CURRICULUM VITAE

PERSONAL DETAILS:

NAME: KUMARDEEP DUTTA CHOUDHURY

ADDRESS:

Permanent: C 403 Prateek Stylome

Sector 45, NOIDA
Pin:201303

Mailing: C 403 Prateek Stylome

Sector 45, NOIDA
Pin:201303

Office: Senior Consultant & Head Of Unit

Dept Of Medical Oncology,
Room No 826, Ground Floor
Action Cancer Hospital
A 4, Paschim Vihar
New Delhi - 110063

E-mail: kumardeep.d@gmail.com

DATE OF BIRTH: December 27, 1972

CURRENT POSITION: Senior Consultant & Head Of Unit

Dept Of Medical Oncology,
Action Cancer Hospital,
A 4, Paschim Vihar
New Delhi - 110063

ACADEMIC DETAILS:

A. MEDICAL EDUCATION :

Graduate: Bachelor of Medicine and Bachelor of Surgery

(MBBS) (1991-1996) from Silchar Medical College, Silchar, Assam.
1993 First Professional Examination, 58.3% marks.
1994 Second Professional Examination 59.4% marks.
1996 Final Professional Examination 57.7% marks.
1
 Post Graduate: Doctor of Medicine (MD) in Internal Medicine
(Dec. 2000- Feb. 2004) from Silchar Medical College, Assam.

DNB (Medical Oncology): In Department of Medical Oncology, Rajiv Gandhi

Cancer (June 2007- May 2010) Institute and Research Centre, Delhi.

DNB (medical oncology) passed in first attempt.

B. SCHOOL EDUCATION

Matriculation (10th Std.): 1989 (Assam Board) with 68% marks.

Intermediate (12th Std.): 1991(Assam Board.) with 75% marks.

CLINICAL TRAINING AND PROFESSIONAL EXPERIENCE

• 1997: 1 year compulsory rotating internship at Silchar Medical College,

Assam.
• 1998-1999: Junior Resident in the Department of Casualty and ENT at
Deen Dayal Upadhyaya Hospital, New Delhi.

• 1999- 2000: Junior Resident in the Department of Medicine,at Silchar

Medical College, Assam.

• 2004- 2005: Senior Resident in the Department of Medicine,at

Deen Dayal Upadhyaya Hospital, New Delhi.

• 2005- 2006: Senior Resident in the Department of Medical

Oncology at Cachar Cancer Hospital, Silchar

• 2006- 2007: Training in Medical Oncology from TATA Memorial Hospital,

Mumbai.

• June 2010- Aug. 2010 ;Clinical Assistant in the Department of

Medical Oncology, Rajiv Gandhi Cancer Institute
and Research Centre, Delhi

2
Aug. 2010- May. 2011 Associate Consultant in the Department of
Medical Oncology, Rajiv Gandhi Cancer Institute
and Research Centre

May 2011 to Oct 2011 Attending Consultant in Dept. of Medical Oncology,

Indraprastha Apollo Hospital

November 2011 to August 2019 Consultant in Dept. of Medical Oncology,

Rajiv Gandhi Cancer Institute and
Research, Centre, Rohini, Delhi

August 2019 to 31/12/2020 Senior Consultant & Head Of Department

Dept Of Medical Oncology, IOSPL
Fortis Hospital Noida and Faridabad

01/01/2021 to till date Senior Consultant & Head of Unit

Dept of Medical Oncology
Action Cancer Hospital,
A 4, Paschim Vihar
New Delhi - 110063

LICENSURE: Registration No: 14015, Medical Council of India.

Registration No. 23770, DMC dated 23.07.10.

RESEARCH EXPERIENCE

2001- 2003: Submitted the MD Thesis titled "Hematological

profile of
(MD Thesis) patients with chronic renal failure" to School of
Medical
Sciences, Assam University, Silchar.

2008-2010: “Effect of neo- adjuvant chemotherapy in locally

advanced (DNB Dissertation) breast cancer”, Rajiv
Gandhi Cancer Institute and Research Centre, Delhi

CLINICAL TRIAL EXPERIENCE:

Co-Investigator in following clinical trials:

3
1. A Phase III trial to compare the safety and efficacy of Lapatinib plus trastuzumab plus an
aromatase inhibitor (Al) versus trastuzumab plus an Al versus lapatinib plus an Al as first
line therapy in postmenopausal subjects with hormone receptor positive, HER2-positive
metastatic breast cancer (MBC) who have received prior trastuzumab and endocrine
therapies

2. Protocol BM200-CT3-001-11;Comparative PK, efficacy, safety and immunogenicity

evaluation of Bmab-200 versus Herceptin®, both in combination with Docetaxel in patients
with Her2+ metastatic breast cancer: A double blind, randomaised, active control, parallel
assignment, comparative phase III, clinical trial with a post-trial open-label extension phase

3. A Multicentre, Phase III, open label, randomized study in patients with advanced follicular
lymphoma evaluating the benefit of maintenance therapy with Rituximab (Mabthera) after
induction of response with chemotherapy plus Rituximab in comparision with no
maintenance therapy. (Study protocol No PRIMA (2004-CO 1756-36).
4. Protocol: CLDK378A2301. A phase III multicenter, randomized study of oral LDK378
versus standard chemotherapy in previously untreated adult patients with ALK rearranged
(ALK- positive), stage IIIB or IV, non-squamous non-small cell lung cancer.

5. EPO-ANE-3010/Amendment INT-1: A Randomized Open-Label, Multicenter, Phase III

Study of Epoetin Alfa plus Standard Supportive Care versus Standard Supportive care in
Anemic Patients with Metastatic Breast Cancer Receiving First-Line Standard
Chemotherapy.

6. CLDK378A2402. “An open-label, multi-center, Expanded Treatment Protocol (ETP) of oral

LDK378 in adult patients with non-small celllung cancer (NSCLC) characterized by ALK
positivity” having study number CLDK378A2402
7. A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to
compare the safety and efficacy of Bevacizumab of Intas Pharmaceuticals Limited against
Avastin™ in Patients with Unresectable or Metastatic Non-Squamous Non-Small Cell Lung
Cancer.

8. 113-10 NPLS extension study

9. Protocol Title: A Phase IV, Multicenter, Open-Label, Single-Arm Study Of Pertuzumab (In
Combination With Trastuzumab And Docetaxel) In First Line Treatment of Indian Patients
With Her2- Positive Advanced (Metastatic Or Locally Recurrent) Breast Cancer;
10. Protocol Title: An Indian Multicentric Open Label Prospective Phase IV Study To Evaluate
Safety And Efficacy Of Trastuzumab In Her2 Positive, Node Positive Or High Risk Node
Negative Breast Cancer As Part Of A Treatment Regimen Consisting Of Doxorubicin,
Cyclophosphamide, With Either Docetaxel Or Paclitaxel(AC→TH) Or Docetaxel And
Carboplatin (TCH); Protocol Number: ML28714 ;

4
 11. Protocol #ML29662: A multicentre open label, single arm, phase IV study of trastuzumab

emtansine in Indian patients with Her2 Positive unresectable locally advanced or metastatic breast
cancer who have received prior treatment with trastuzumab anda taxane.
12. A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and
Cyclophosphamide Administered at Different Doses /Regimens with Metronomic Schedule in
Patients with Metastatic Breast Cancer.

13. A multi-center (two-center), open-label, non-randomized, study to evaluate the

tolerability, safety and possible effects of a plant phospholipid/lipid conjugate (pPLC)in

patients with inoperable metastatic pancreatic cancer receiving standard of care treatment.

14. A study of palbociclib in combination with letrozole as treatment of post menopausal

womenwith hormonal receptor positive, her2 negative and advanced breast cancer for whom

letrozole therapy is deemed.

Principal-Investigator in following clinical trials:

1) CLDK378A2402. “An open-label, multi-center, Expanded Treatment Protocol (ETP) of oral

LDK378 in adult patients with non-small celllung cancer (NSCLC) characterized by ALK
positivity” having study number CLDK378A2402

2) A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and

Cyclophosphamide Administered at Different Doses /Regimens with Metronomic Schedule in
Patients with Metastatic Breast Cancer

3) A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of

Avelumab(MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone as a
MaintenanceTreatment in Patients with Locally Advanced or Metastatic Urothelial Cancer
Whose Disease Did Not Progress After Completion of First-Line Platinum-Containing
Chemotherapy

TEACHING EXPERIENCE

2000- 2003: Medical student as Junior Resident, Internal

Medicine, Silchar Medical College
5
2007- 2010: Medical students and Senior Resident, Medical
Oncology, Rajiv Gandhi Cancer Institute and
Research Centre, Delhi

2010 to August 2019: Fellows (training for the degree of DNB.) in

Medical Oncology at Rajiv Gandhi Cancer Institute
and Research Centre, Delhi

Thesis guide of DNB (Medical Oncology) students

CONFERENCES ORGANIZED AND ATTENDED-

1. Participated and stood First in quiz on medicine in APICON, 2002.

2. Participated in APICON, BHU, Varanasi in 2003.

3. Attended the XIII th National CME in Hematology held at Bombay Hospital, Mumbai in
January 2007.

4. Attended an international conference on “Hematopoietic Stem Cell Transplantation”

organized by GCRI, Ahmedabad in January 2007.

5. Attended CME on CML organized by RGCI & RC, New Delhi in October 2007.

6. Attended the Fifth TMH- WCI conference on “Advanced Breast Cancer and Ovarian Cancer”
organized by TMH, Mumbai in October 2007.

7. Organized RGCON on Colorectal Cancer, RGCI, New Delhi in March 2008.

8. Organized RGCON on Lung and Esophageal Cancer, RGCI, New Delhi in March2009.

9. Participated in the Golden Jubilee Conference of Indian Society of Hematology & Transfusion
Medicine Organized by Deptt. Of Hematology, AIIMS, New Delhi in November 2009.

10. Organized RGCON on Organ Preservation Strategy, RGCI, New Delhi in March 2010.

11. Participated in a workshop on Biomedical Communication organized by RGCI and ICMR in

May 2010.

12.APICON 2014 Lecture on Management of Multiple myeloma

6
13. Participated in 34th ICON (Joint Conference of Indian Cooperative Oncology Network and
Molecular Oncology Society) on 11th March 2016 on Talk beyond ALK first line therapy.

14. Participated as faculty/ speaker in 4th Kolkata Breast Cancer Symposium on Saturday 7th May
2016 on “That all TNBC should receive a platinum agent in Adjuvant settings”.

15. Participated in Centre of Excellence program 2016 of National Cancer Centre Singapore on
18-19th August 2016.

16. Participated as Speaker on “Tumor marker in oncology diagnosis: uses and limitations” on3 rd
international clinical oncology conference organized by SFO-N on 24th September 2016 at
Kathmandu, Nepal.

17. Participated as faculty/panelist on “New Targets: New drugs in Multiple Myeloma” in

ISMPOCON Delhi, 6th Nov 2016.

18. Participated as faculty on Osteosarcoma Update 2016 on 13th November 2016.

19. Participated In 17th IASLC WCLC 2016 3rd to 7th December in Vienna, Austria

20. Participated as Faculty in Best of WCLC at Delhi on 25th December 2016

21. Participated as faculty in Update on Oncology-X: Challenging Common Case Scenarios in

Breast Cancer” on 07/05/17 at SGRH, Delhi

22. Speaker at RIME: Neo-adjuvant treatment of Breast cancer: Medical Oncologist perspective
on 19/05/17 at Delhi

23. Faculty in 1st Annual Indian Breast Cancer Conference, Jaipur, 7th-8th Oct, 2017

24. Faculty in Best Of WCLC 2017, India, Delhi, 29 th Oct, 2017

25. Faculty in Best Of SABCS, India, Delhi 20-21 April, 2018

26. Speaker on Role of chemotherapy in breast Cancer in HCG Apex Breast Conclave- Cure,
Cosmesis and Beyond. Mumbai, 19-20th May, 2018

27. Faculty in Best Of ASCO, India, Coimbatore 6th-8th July, 2018

28. Faculty in 2nd Annual Indian Breast Cancer Conference, Jaipur, 5th-7th Oct, 2018

29. Faculty in Best of WCLC, India, Delhi 14th Oct, 2018

30. Korean Association of Lung Cancer Conference 22nd-24th Nov, 2018.

7
31. Delegate 3rd ELEVATE meeting on Breast Cancer Update in Viena 17th -18th May 2019

32 Speaker 3rd Annual International Precision Oncology & Breast Cancer Conference || 11th
October to 13th Octobert, 2019, Jaipur,

33 Faculty in Immuno oncology Summit, Delhi 09th November 2019

34 Programme Director of SYNERGY 2019, an update on Lung and Breast Cancer, on 2nd
November 2019 at India Habitat Centre, Delhi
35. Talk On Breast Cancer Update at UPICON, Meerut on 21st Dec 2019
35. Faculty for the Venkateshwar cancer centre ONCO SUMMIT 2020, on 11th Jan 2020
36. Presented Abstract ID 1002- TBCRC 048 A phase II study of Olaparib monotherapy in
metastatic breast cancerpatients with germline or somatic mutations in DNA damage response
pathway genes ( Olaparib extended). 26th June 2020 on Best of ASCO India Webinar.

37. Practice changing Breakthroughs in Abdominal and Lung cancers: ONCOWEBEX 2020 as a
faculty in gastro entero pancreatic neuroendocrine tumors. 29th Sept 2020.

38. As A Faculty in Innovations in Oncology, in Newer Challenges in Her 2 neu breast cancer in
2020. 24th Oct 2020.

MAJOR INTERESTS:

1. Breast cancer
2. Epithelial ovarian cancer.
3. Colorectal cancer
4. Lung cancer
5. Lymphomas

PAPERS PRESENTED/ PUBLICATIONS:

1. D.C. Kumardeep, Sharma P.C, P.R.N. Borbhuiya, Medical Complications of obesity, presented
at APICON (Assam Chapter) 2002.

2. D.C. Kumardeep, Sharma P.C, Prevelance of Dyslipidemia in healthy general population of

Silchar town, presented at APICON (Assam Chapter) 2002.

3. D.C. Kumardeep, Sharma P.C, Management of Dyslipidemia, published as update article in

APICON (Assam Chapter) 2002.

8
4. D.C. Kumardeep, Gupta D, Agarwal A, Bhurani D, Response to Imatinib in Chronic Myeloid
Leukemia by Cytogenetics, presented at Golden Jubilee Conference of Indian Society of
Hematology & Transfusion Medicine Organized by Deptt. Of Hematology, AIIMS, New Delhi,
2009.

5. Choudhury KD, Doval DC, Azam S, Mehta A, Pruthi A, Batra U, Kumar K.

A report of sarcomatoid carcinoma of the gall bladder treated with palliative docetaxel and
gemcitabine chemotherapy. J Gastroinstestinal cancer, 2014 Dec;45 Suppl 1;270-4,doi: 10.1007/s
12029-014-9654-3.PMID: 25326734

6. Dutta K, Doval DC, Batra U,Talwar V. Neoadjuvant chemotherapy in breast cancer: review of
literature.J Indian Medical Association 2013 Sep;111(9):629-31. Review.
PMID: 24968534

7. Choudhury KD, Doval DC, Azam S, Batra U, Talwar V,Gupta SK,Mehta A.Epidermal growth
factor receptor muatio in lung adenocarcinoma in India: A single center study.
J Carcinog.2013 Jul 12;12;12.doi:10.4103/1477-3163.114970.e Collection 2013PMID:23961259
8. K. Dutta, A. Upadhyay, V. Goel, U. Batra, P. Goyal, M. Aggarwal, D. C. Doval Two cases of
ovarian carcinoma with endobronchial metastases: Rare presentation. South Asian Journal of
Cancer. Vol 4, Issue 3, July – Sept 2015.

9.DC Kumardeep, DC Doval, Singha R et al. Profile of Anaplastic Lymphoma Kinase Fusion
Oncogene Positive Patients with Non Small Cell Lung Cancer. J of Carcinogenesis Vol15, April
2016.

10. DC Kumardeep, Sharma A, Doval DC et al: Efficacy and safety profile of eribulin mesylate in
advanced breast cancer. Single centre experience from India. Accepted for Poster
presentation(display) at ESMO Asia 2016 Congress. 16-19 December 2016

11. Kumardeep Dutta, Chaturbhuj Ramanand Agrawal, , Dinesh Chandra Doval, Sunil Pasricha,
Manoj Gupta Breast Cancer Recurrence Presenting as Solitary Intraparotid Nodal Metastasis
Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography: A Very Unusual
Occurrence. Indian J Nucl Med. 2018 Jul-Sep; 33(3): 233–236. doi: 10.4103/ijnm.IJNM_17_18

12. Kumardeep Dutta, Chaturbhuj R Agrawal, Pankaj Goyal, Dinesh Chandra Doval, Kshitij
Domadia, Silky Kothiwal. Eyelashes Trichomegaly: An Unusual Side Effect of Gefitinib
TherapyInt J Trichology. 2018 Jan-Feb; 10(1): 44–46. doi: 10.4103/ijt.ijt_72_17

13. Kumardeep Dutta, Moushumi Suryavanshi, Anurag Mehta, Manoj Kumar Panigrahi, Jiten
Jaipuria, Mumtaz Saifi, Kavita Jain, Dushyant Kumar, Haristuti Verma, Sanjeev Kumar Sharma,
Ullas Batra, Vineet Talwar, Dinesh Chandra Doval.The detection of primary and secondary EGFR
mutations using droplet digital PCR in patients with nonsmall cell lung cancer Lung India. 2018
Sep-Oct; 35(5): 384–389. doi: 10.4103/lungindia.lungindia_472_17

9
14. Kumardeep Dutta Choudhury, Dinesh Chandra Doval, Mithun Chacko, Rupal Sinha, Ajay
Sharma, Avinash Rao, R. S. Jaggi, Anurag Mehta. A rare case of brain metastasis in a patient with
osteosarcoma. South Asian J Cancer. 2017 Jan -Mar; 6(1): 36–37. doi: 10.4103/2278-
330X.202572

15. Gupta M1, Choudhury PS1, Rawal S2, Goel HC3, Talwar V4, Dutta KD4, Singh A2.Safety
profile and therapeutic efficacy of one cycle of [177Lu]prostate-specific membrane antigen
(PSMA) in end stage metastatic castration-resistant prostate cancer patients with low performance
status. Ann Oncol. 2019 Feb 1;30(Supplement_1).

16. Agrawal CR1, Goyal P1, Doval DC1, Dutta K1, Domadia K1, Kothiwal
SEyelashes Trichomegaly: An Unusual Side Effect of Gefitinib Therapy. Int J Trichology. 2018
Jan-Feb;10(1):44-46. doi: 10.4103/ijt.ijt_72_17.

17. Agrawal CR1, Dutta K1, Doval DC1, Pasricha S2, Gupta
M3Breast Cancer Recurrence Presenting as Solitary Intraparotid Nodal Metastasis Detected by 1
8F-Fluorodeoxyglucose Positron Emission Tomography: A Very Unusual Occurrence.
18. Suryavanshi M, Mehta A, Panigrahi MK, Jaipuria J, Saifi M, Jain K, Kumar D, Verma H,
Sharma SK, Batra U, Dutta K, Talwar V, Doval DC.
The detection of primary and secondary EGFR mutations using droplet digital PCR in patientswi
th nonsmall cell lung cancer. Lung India. 2018 Sep-Oct;35(5):384-389. doi:
10.4103/lungindia.lungindia_472_17.

19. Manoj Gupta, M.D.; Partha Sarathi Choudhury; Sudhir Rawal; Harish Chandra Goel; Vineet
Talwar; Kumar Deep Dutta; Amitabh Singh; Amita Gupta Safety profile and therapeutic efficacy
of one cycle of [177Lu] PSMA in end stage metastatic castration resistant prostate cancer patients
with low performance status. 18 Nov 2019 Nuclear Medicine and Molecular Imaging, Korea
20. Efficacy and tolerability of nimotuzumab in combination with chemotherapy in recurrent and
metastatic squamous cell carcinoma of head and neck at a cancer centre in Northern India.
Abhishek Y, Chaturbhuj A., Kumardeep DC, DC Doval et al. Indian J Cancer Jan- Mar 2020;
57(!):76-83.

21. E Poster: p53 – Role of immune biomarkers in evaluating predictive and prognostic value in
advanced stage Her 2 neu positive breast cancer. Pasricha Sunil, Divya Bansal, Kumardeep DC et
al at virtual ESMO meeting , 2020 Berlin

22. Pathologic Complete Response in primary tumor and axillary nodes and effect on survival in
locally advanced breast cancer. An elevan years single unit experience at a tertiary cancer centre
in India. DC Doval, Rupal T, Kumardeep DC, Harit Chaturvedi et al.Indian Journal Of Sugical
Oncology

23. Prognostic role of micro RNA 182 and micro RNA 18a in locally advanced triple negative
breast cancer. DC Doval, Rajat B., Kumardeep et al. PLos One 15(11) e0242190Nov 11,2020
10
 Manuscript accepted

1. Real world data of response to Trastuzumab based chemotherapy in locally

advanced Her 2 neu positive breast cancer. Manuscript no JCB 20 0376 at
journal of Breast Cancer. By Dr DC Doval, Dr Sneha B., Dr. Kumardeep et
al

Media & Awards:

1. Over 8 lakh deaths due to colorectal cancer in 2018.Expert emphasizes the need for more
screening programs among high-risk groups.By Dr. Kumardeep Dutta Choudhury
• Hindustan Times. Mar 6, 2019
2. EGFR Mutation In Lung Adenocarcinoma In Indian Subcontinent in Docplexus 17th
January, 2019
3. Challenges Associated With Breast Cancer Management in Docplexus 20th March 2019

4. Know about the lifestyle factors that can cause cancer. Hindustan Times, New Delhi, Saturday
Nov 30,2019

5. Samita Mishra Memorial Foundation for Cancer Research Excellence Award for Active
Role and Leadership in Cancer Bhagao Campaign. 2014
6. Most Proactive physician for Adaptation of EHR on 19th Foundation Day at Rajiv Gandhi
Cancer Institute (26/09/15).
7. Bhagirath Samman, Delhi 2017-18 for Social Work
8. Over 8 lakh deaths due to colorectal cancer in 2018.Expert emphasizes the need for more
screening programs among high-risk groups.By Dr. Kumardeep Dutta Choudhury
• Hindustan Times. Mar 6, 2019
9. EGFR Mutation In Lung Adenocarcinoma In Indian Subcontinent in Docplexus 17th
January, 2019
10. Update on Breast Cancer at FOGSD event 21st Jan 2020

11. Cancer Awareness Talk at BPCL, Sec 56 NOIDA on 24th Jan 2020

12. “Know about your lifestyle factors that can cause cancer”, Hindustan Times, New Delhi,
Saturday, Nov 30. 2019
13. “All you need to know about Male Breast Cancer”, Outlook , New Delhi 24Th Jan 2020
14. Corona Warrior Award by Sabka Saath Foundation June 2020.
15. “Awareness can the life of breast cancer patients” Hindustan Times, New Delhi 11th Oct 2020

11
Kumardeep Dutta Choudhury 01/12/2020

12